Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(γ-l-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo

Summary

The antitumor activity of a mitomycin derivative, 7-N-[2-[[2-(γ-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), was evaluated in murine and human tumor models, including a mitomycin C (MMC)-resistant tumor in vitro and in vivo. KW-2149 showed a profound effect against i.p. inoculated P388 leukemia on both a single and an intermittent administration schedule. Against s.c. implanted colon adenocarcinoma 38 (colon 38), KW-2149 was as effective as MMC in ILS% and in tumor growth inhibition on a single-administration schedule. Both compounds were similarly effective when an intermittent schedule was used. KW-2149 showed activity against human tumor xenografts and was effective in two of four non-small-cell lung carcinomas but was not effective against three gastric adenocarcinomas on the singleadministration regimen. The activity of KW-2149 against gastric adenocarcinoma was inferior to that of MMC on a single-administration schedule. However, the antitumor activity of KW-2149 was higher on an intermittent schedule than on a single-administration regimen. The antitumor activity of KW-2149 against human tumor xenografts was similar to that of MMC on an intermittent schedule, and the former drug was effective against both gastric adenocarcinomas and both non-small-cell lung carcinomas. KW-2149 was more effective than MMC against a subline of P388 leukemia that is resistant to MMC in vitro as well as in vivo.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Cosulich DB, Patric JB, Williams RP (1960) Reaction products of mitomycin and porfiromycin. United States Patent 321440 (CI, 260-319), October 26, 1959 (Chemical abstract 64, P533c)

  2. 2.

    Geran RL, Greenberg NH, MacDonald MM, Schumacher AM, Abbott BJ (1972) Protocol against animal tumor and other biological system. Cancer Chemother Rep 3: 1

  3. 3.

    Imai R, Ashizawa T, Urakawa C, Morimoto M, Nakamura N (1980) Antitumor activity of 7-N-phenyl derivatives of mitomycin C in leukemia P388 system. Gann 71: 560

  4. 4.

    Inaba M, Fujikura R, Sakurai Y (1979) Comparative study on in vivo development of resistance to various classes of antitumor agents in P388 leukemia. Gann 70: 607

  5. 5.

    Inaba M, Tashiro T, Kobayashi T, Sakurai Y, Maruo K, Ohnishi Y, Ueyama Y, Nomura T (1988) Responsiveness of human gastric tumors implanted in nude mice to clinically equivalent doses of various anticancer agents. Jpn J Cancer Res 79: 517

  6. 6.

    Iyengar BS, Sami SM, Remers WA, Bradner WT, Schurig JE (1983) Mitomycin C and porfiromycin analogues with substituted ethylamine at position 7. J Med Chem 26: 16

  7. 7.

    Kono M, Saito Y, Kasai M, Sato A, Shirahata K, Morimoto M, Ashizawa T (1989) Synthesis and antitumor activity of 7-N-[2-[2-(γ-l-glutamylamino)ethyl]dithio]ethyl]mitomycin C. Chem Pharm Bull 37: 1128

  8. 8.

    Morimoto M, Ashizawa T, Akinaga S, Azuma M, Kono K, Saito T, Sato A, Kasai K (1988) Antitumor activity of 7-N-[2-[2-(γ-l-glutamylamino)ethyl]dithio]ethyl]mitomycin C. Proc Am Assoc Cancer Res 29: 266

  9. 9.

    Morimoto M, Ashizawa T, Ohno H, Azuma M, Kobayashi E, Okabe M, Gomi K, Kono M, Saitoh Y, Kanda Y, Arai H, Sato A, Kasai M, Tsuruo T (1990) Antitumor activity of 7-N-[2-[2-(γ-l-glutamylamino)ethyl]dithio]ethyl]mitomycin C. Cancer Res (in press)

  10. 10.

    Sami SM, Iyengar BS, Tarnow SE, Remers WA, Bradner WT, Schurig JE (1983) Mitomycin C analogs with secondary amine at position 7. J Med Chem 26: 1453

  11. 11.

    Tashiro T, Inaba M, Kobayashi T, Sakurai Y, Maruo M, Ohnishi Y, Ueyama Y, Nomura T (1989) Responsiveness of human lung cancer/nude mouse to antitumor agents in a model using clinically equivalent doses. Cancer Chemother Pharmacol 24: 187

  12. 12.

    Tomasz M, Lipman R, Chowday D, Rawlack J, Verdine GL, Nakanishi K (1987) Isolation and structure of a covalent cross-link adduct between mitomycin C and DNA. Science 235: 1204

  13. 13.

    Tsuruo T, Iida H, Tsukagashi S, Sakurai Y (1981) Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967

  14. 14.

    Usubichi I, Sobajima Y, Hongo T, Kawaguchi T, Sugayashi M, Matsui M, Wakagi S, Uzu K (1967) Antitumor studies on mitomycin derivatives: effect on Hirosaki ascites sarcoma. Gann 58: 307

  15. 15.

    Watanabe M, Kumeshima N, Nakajima S, Tsuruo T (1988) MX 2, a morpholine anthracycline, as a new antitumor agent against drugsensitive and multidrug-resistant human and murine tumor cells. Cancer Res 48: 6653

  16. 16.

    Wilson JKV, Long BH, Chakrabarty S, Brattain, DE, Brattain MG (1985) Effect of BMY25282 a mitomycin C analogue in mitomycin C-resistant human colon cancer cells. Cancer Res 45: 5281

Download references

Author information

Correspondence to Takashi Tsuruo.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tsuruo, T., Sudo, Y., Asami, N. et al. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(γ-l-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo. Cancer Chemother. Pharmacol. 27, 89–93 (1990). https://doi.org/10.1007/BF00689089

Download citation

Keywords

  • Ethyl
  • Adenocarcinoma
  • Antitumor Activity
  • Human Tumor
  • Lung Carcinoma